Literature
Left Atrial Strain Predicts Outcome in Populations With and Without Specific Cardiovascular Diseases Across the Range of Ejection Fraction: A Systematic Review and Meta-Analysis.
Signal observed that left atrial strain (LAS) measured by speckle-tracking echocardiography serves as a powerful predictor of major cardiovascular events across different patient populations and ejection fraction ranges. Evidence suggests LAS independently predicts composite outcomes of all-cause death and heart failure hospitalizations in patients with heart failure (HR 0.93), ischemic heart disease, and valvular heart disease, but not in those with left ventricular hypertrophy. Worth noting that this prognostic value appears consistent regardless of left ventricular ejection fraction values, potentially offering an additional assessment tool beyond traditional metrics.
LAS represents a powerful predictor of major cardiovascular events in the general population and in patients with different cardiovascular diseases across left ventricular ejection fraction...
Relevance: Systematic review and meta-analysis of left atrial strain predicting cardiovascular outcomes across ejection fraction ranges, including heart failure populations. Relevant to heart failure research interest and cardiac assessment, though not specific to pediatric congenital disease or single-ventricle physiology.
PMID: 42206564Echocardiography (Mount Kisco, N.Y.)(Journal Article) Literature
Stem-Cell-Derived Biologic Ventricular Assist Tissue in Heart Failure.
Signal observed from this phase 1-2 study that biologic ventricular assist tissue (BioVAT) composed of engineered heart muscle from stem cell-derived cardiomyocytes shows measurable cardiac remuscularization effects in heart failure patients. Evidence suggests treatment with 20 engineered-heart-muscle units resulted in significant increases in target heart-wall thickness (4.5 mm) and left ventricular ejection fraction (3.9 percentage points) at 3 months, though all patients experienced at least one adverse event. Worth noting this represents a novel tissue engineering approach to cardiac repair that differs fundamentally from traditional pharmacological or device-based heart failure interventions.
(Funded by the German Center for Cardiovascular Research and Repairon; BioVAT-HF ClinicalTrials.gov number, NCT04396899.).
Relevance: Phase 1-2 study of biologic ventricular assist tissue for heart failure with reduced ejection fraction. Directly relevant to heart failure research interest with novel therapeutic approach, though focuses on adult rather than pediatric population.
PMID: 42202318The New England journal of medicine(Journal Article) Literature
Impact of concomitant left-sided valve disease on outcomes following tricuspid valve transcatheter edge-to-edge repair: insights from EuroTR.
Signal observed from the EuroTR registry that concomitant moderate or greater left-sided valvular disease significantly impacts outcomes in patients undergoing tricuspid edge-to-edge repair, with reduced 2-year survival and increased heart failure hospitalizations. Evidence suggests that while ≥moderate left-sided valve disease serves as an independent mortality predictor (HR 1.54), tricuspid repair still provides meaningful symptom improvement and durable tricuspid regurgitation reduction even in these higher-risk patients. Worth noting that left-sided valve disease burden appears common in this population, affecting over one-third of patients at moderate or greater severity.
Nevertheless, T-TEER provides meaningful symptomatic benefit and durable TR reduction in patients with and without VHD burden.
Relevance: Study of tricuspid edge-to-edge repair outcomes in adult patients with concomitant left-sided valve disease and heart failure hospitalization endpoints. Related to heart failure research interest and tricuspid disease management in complex patients, though adult-focused rather than pediatric or Fontan-specific.
PMID: 42159136ESC heart failure(Journal Article)